Sure. So we're very excited about the Phase III readout expected next quarter. Avexitide, our lead asset has been through 5 prior trials, all of which showed highly statistically significant effects on glucose and insulin. And then in the Phase II and Phase IIb, we studied the rate of Level 2 and Level 3 hypoglycemia, which showed quite a strong effect as well. So under that backdrop for the Phase III, our goal is to try to keep as much consistent as we possibly could. So very similar inclusion/exclusion cr ...